Organizations Filed Purposes:
Research, education and support for victims of Alzheimer's, their families, caregivers and the public
Biogen: Emerge Study - To study the efficacy and safety of an investgational medication called Aducanmab in people experiencing symptoms of early Alzheimer's disease. It is thought that Aducanumab recognizded harmful amyloid plaques found in the brain of people with Alzheimer's disease. The study will determine if the investigational medication can remove the plaques and slow the progression of the disease.
Roche - Cread Crenezumab Protocol - This is a Phase III randomized, double-blinded, placebo-controlled sudy to evaluate the safety and efficacy of crenezumab (a fully humanized monoclonal antibody) in patients with initial to mild Alzheimer's disease. The study involves biweekly infusions of the drug to ascertain any change in their disease systems.
Lilly - Navigate - AD Study - Participated in an international investgational drug study to determine the possible effect of the study drug on the protein "Tau" build-up inside the brain. The study involves oral dosing of patient over a period of 52 weeks with a follow-up period to determine any effect on the buildup of Tau and other related Alzheimer's symptoms. The study also records and unwanted side effects.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Monika Moseley | Director | 1 | $0 |
| John L Wotring | President | 1 | $0 |
| John J Wotring | Treasurer | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/201941319349300519_public.xml